Gene487
ATP2A1: ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1
13 sourcesgene-search-2026-11-13-0.2.1
Cite this record
ConductScience Library. ATP2A1: ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1. Genes, record 487. Release gene-search-2026-11-13-0.2.1, 13 Nov 2026. https://conductscience.org/library/genes/487
Gene
Connected records6
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Drugs and targets1
Diseases5
- prostate cancer1 of its drugs acts on it757 drugs, 2,173 trials
- hepatocellular carcinoma1 of its drugs acts on it478 drugs, 1,505 trials
- glioblastoma1 of its drugs acts on it453 drugs, 1,058 trials
- clear cell renal carcinoma1 of its drugs acts on it106 drugs, 160 trials
- adenocarcinoma1 of its drugs acts on it89 drugs, 95 trials
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O14983 | Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | 1,001 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents74
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 20260193644 A1 | 2026-07-09 | 7333 | O14983 | Espacenet |
| US 20260139247 A1 | 2026-05-21 | 505 | O14983 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 38163 | O14983 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 7333 | O14983 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 505 | O14983 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 505 | O14983 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 505 | O14983 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 7333 | O14983 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 7232 | O14983 | Espacenet |
| US 20240398993 A1 | 2024-12-05 | 21084 | O14983 | Espacenet |
Drugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| MIPSAGARGIN | CHEMBL3989865 | Sarcoplasmic/endoplasmic reticulum calcium ATPase inhibitor | INHIBITOR |
Source ChEMBL
Trials7
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT02876003 | MIPSAGARGIN | PHASE2 | ClinicalTrials.gov | |
| NCT02607553 | MIPSAGARGIN | PHASE2 | ClinicalTrials.gov | |
| NCT02381236 | MIPSAGARGIN | PHASE2 | ClinicalTrials.gov | |
| NCT02082691 | MIPSAGARGIN | ClinicalTrials.gov | ||
| NCT02067156 | MIPSAGARGIN | PHASE2 | 2024-05-21 | ClinicalTrials.gov |
| NCT01777594 | MIPSAGARGIN | PHASE2 | ClinicalTrials.gov | |
| NCT01734681 | MIPSAGARGIN | PHASE2 | ClinicalTrials.gov |
NIH grants987
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ATP2A1 papers | Newest fiscal year |
|---|---|---|---|
| P30DK020541 | NYR-Diabetes Research Center (NYR-DRC) | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 3 | 2025 |
| R01DK093757 | Genetic epidemiology of rare and regulatory variants for metabolic traits | 3 | 2025 |
| R01DK097441 | Molecular mechanisms of UCP1-independent pathways in metabolic health | 3 | 2025 |
| R01ES014901 | Molecular and Cellular Basis of PCB Developmental Neurotoxicity | 3 | 2025 |
| T32HL007055 | Cardiovascular Epidemiology Training Grant | 3 | 2025 |
| U10AA008401 | Collaborative Study on the Genetics of Alcoholism (COGA). | 3 | 2025 |
| UL1TR002345 | Washington University Institute of Clinical and Translational Sciences | 3 | 2025 |
| P01HD084387 | Developmental Mechanisms of Human Idiopathic Scoliosis | 2 | 2025 |
Source NIH's project files
Papers1,220
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prognostic value of neuro-related genes in colorectal cancer and their potential implications for immunotherapy. | J Cancer | 2026 | 42807766 | PubTator, text mining | PubMed |
| miR-20487-5p/SERCA1/MAPK/ERK Pathway Regulates Newt Limb Regeneration. | Biology (Basel) | 2026 | 42510654 | PubTator, text mining | PubMed |
| Shared Genetics of Kidney Function Traits and Bladder Cancer: A Genome-Wide Cross-Trait Analysis. | Cancer Med | 2026 | 42470241 | PubTator, text mining | PubMed |
| Activation of Sirt3 reprograms mitochondrial function to regenerate intervertebral disc degeneration. | Exp Gerontol | 2026 | 42401268 | PubTator, text mining | PubMed |
| Sebastidae-specific food allergy causing anaphylaxis: a pediatric case report and fish allergen analysis. | BMC Pediatr | 2026 | 42129685 | PubTator, text mining | PubMed |
| The SERCA Pump: A Key Molecular Target in Calcium Handling of Vascular Smooth Muscle Cells in Metabolic Syndrome. | Handb Exp Pharmacol | 2026 | 42113224 | PubTator, text mining | PubMed |
| The pleiotropic impact of chaperone-mediated autophagy on skeletal muscle integrity. | Autophagy | 2026 | 42003010 | PubTator, text mining | PubMed |
| Sarco/endoplasmatic reticulum calcium ATPase activity in healthy muscle and Brody disease. | Biochem Biophys Rep | 2026 | 41938373 | PubTator, text mining | PubMed |
| Rare Brody myopathy: A case report. | J Am Assoc Nurse Pract | 2026 | 41926432 | PubTator, text mining | PubMed |
| Evaluating Toxicity and Anti-Osteogenic Activity of Artemisinin-Inspired Endoperoxides in Zebrafish Larvae. | Toxics | 2026 | 41893529 | PubTator, text mining | PubMed |
Sources 13
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
- USPTO's sequence listingsPublic domain in the US. Source: United States Patent and Trademark Office, www.uspto.gov
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
- USPTO's sequence listingsUSPTO's sequence listings of patents and published applications, from its bulk data files. No license named for the files. USPTO's terms say "most government-produced materials appearing on this website are not subject to copyright restrictions within the United States and are therefore in the public domain", and ask that USPTO be given appropriate acknowledgement ("Source: United States Patent and Trademark Office, www.uspto.gov"). USPTO does not endorse ConductScience or this release. Read on 12 Nov 2026 at https://www.uspto.gov/terms-use-uspto-websites
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
Source: United States Patent and Trademark Office, www.uspto.gov. USPTO does not endorse ConductScience or this database.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/487
GET https://conductscience.org/api/genes/v1/487/patents?page=2